Syndax Pharmaceuticals (SNDX) Retained Earnings (2015 - 2026)

Syndax Pharmaceuticals' Retained Earnings history runs 12 years deep, the most recent figure standing at -$1.5 billion for Q1 2026.

• On a quarterly basis, Retained Earnings fell 18.63% year-over-year to -$1.5 billion in Q1 2026; TTM through Mar 2026 was -$1.5 billion, a 18.63% decrease from a year earlier, with the FY2025 full-year figure at -$1.5 billion, down 23.37% from the prior year.
• Retained Earnings fell to -$1.5 billion in Q1 2026 per SNDX's latest filing, from -$1.5 billion in the prior quarter.
• Across five years, Retained Earnings topped out at -$580.9 million in Q1 2022 and bottomed at -$1.5 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$974.8 million (2024), against an average of -$1.0 billion.
• Across the five-year window, Retained Earnings rose 2.6% in 2022 and tumbled 35.79% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$693.0 million in 2022, then slumped by 30.21% to -$902.4 million in 2023, then plunged by 35.32% to -$1.2 billion in 2024, then fell by 23.37% to -$1.5 billion in 2025, then retreated by 2.83% to -$1.5 billion in 2026.
• Per Business Quant, the three latest SNDX Retained Earnings figures stand at -$1.5 billion (Q1 2026), -$1.5 billion (Q4 2025), and -$1.4 billion (Q3 2025).